| Literature DB >> 35096369 |
Omar A Alhroub, Shimaa A Mahameed, Mohammad O Abdelhafez, Asil Alhroub, Hani Hour, Nabil Hasasna, Nazmi Kamal.
Abstract
Glomus tumors are rare and usually benign. The malignant form (glomangiosarcoma) comprises <1% of all glomus tumors. There are limited reports that describe glomus tumors in the nasal cavity. However, to the best of our knowledge, glomangiosarcoma of the nasal cavity was never reported in humans. We report on the first case of nasal cavity glomangiosarcoma in a 59-year-old male who presented with a bleeding mass in his right nostril. We completely excised the lesion with a 0.7-mm free margin, and the histopathologic examination was consistent with glomangiosarcoma. A 6-month follow-up illustrated no evidence of recurrence or distant metastasis. Although it is rare, glomus tumors should be in the differential diagnosis of nasal cavity tumors. Histopathologic examination is essential for glomangiosarcoma diagnosis. Treatment requires complete excision with free margin, alongside careful clinical and radiological follow-up. Published by Oxford University Press and JSCR Publishing Ltd.Entities:
Keywords: glomangiosarcoma; glomus tumor; nasal cavity
Year: 2022 PMID: 35096369 PMCID: PMC8791658 DOI: 10.1093/jscr/rjab641
Source DB: PubMed Journal: J Surg Case Rep ISSN: 2042-8812
Figure 1Computed tomography scan of the head. (A) Axial view and (B) coronal view demonstrating mass lesion in the right nasal cavity attached to the septum measuring 1 × 1.5 cm.
Figure 2(A) Intermediate-power field (×20) shows marked nuclear atypia and pleomorphism. (B) High-power field (×40) shows proliferation of atypical spindle cells with atypical mitotic figures (C) High-power field (×40) shows focal areas of necrosis.
Figure 3(A) High-power field (×40) shows immunoreactivity for SMA; (B) high-power field (×40) shows focal immunoreactivity for CD34.
Figure 4(A) Intermediate-power field (×20) shows negative ERG staining by the tumor cells. (B) Intermediate-power field (×20) shows negative S100 staining by the tumor cells. (C) Intermediate-power field (×20) shows negative CD31 staining by the tumor cells.